Exhale

The official blog of the Lung Institute.

Lung Transplant Survival Rates

Lung Transplant Survival Rates for One Month, One Year, and Three Years

Since 2007, national Lung Transplant Survival Rates have remained stable, while short-term survival rates of 30 days and one year have steadily improved. For patients with advanced lung disease, a lung transplant can improve their prognosis. Those who undergo a successful lung transplant operation often survive three years or more after surgery. According to the National Heart, Lung, and Blood Institute at the National Institutes of Health, more than half of single-lung-transplant patients survive at least five years after surgery.

Lung transplant prognosis depends on factors which include:

  • age, gender, and diagnosis
  • length of time the organ was stored before transplantation
  • type of lung transplant (left, right, or double lung)
  • patient response to anti-rejection medications
  • whether the patient has experienced a previous lung transplant

The Scientific Registry of Transplant Recipients (SRTR) released the following statistics

in its July 2015 report:

  • the national one-month adult expected survival rate is 96.85 percent.
  • the national one-year adult expected survival rate is 87.47 percent.
  • the national three-year adult expected survival rate is 68.23 percent.

Many people who suffer from lung disease have slowed the progression of their ailment following cellular therapy at the Lung Institute. If you or a loved one suffers from COPD, contact one of our patient coordinators today by calling 888-745-6697 to see if you are a candidate for cellular therapy.

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months of COPD patients.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.